Cloud-based software as a service company that specializes in online survey development, SurveyMonkey (NASDAQ: SVMK), reported first-quarter losses that were narrower than what the street anticipated. Adjusted net loss for the quarter was 2 cents per share, compared to 15 cents per share projected by the street.
Q1 revenues improved 17% to $68.6 million, edging past the average analysts’ expectation of $68.23 million. Enterprise sales revenue was approximately 16% of total revenue, up from about 13% in Q4.
The stock gained 7.9% during extended trading hours on Wednesday. SVMK shares have gained 45% since the beginning of this year.
The company, which debuted on Nasdaq in September last year, said its paid users at the end of the quarter were 670,862, 10% higher than the same period last year. The average revenue per user (ARPU) grew 8% year-over-year to $423.
CEO Zander Luries said, “Our paying user growth continues to accelerate driven by sales of SurveyMonkey Enterprise and adoption of our collaborative Teams plans with approximately 90% of the net adds in the quarter from annual plans.”
Outlook
For the second quarter, the company expects revenue in the range of $72-73 million, suggesting 15-16% year-over-year growth. Non-Gaap operating margin is projected to be negative four to negative two percent.
READ: LYFT POSTS MASSIVE LOSSES IN ITS MAIDEN EARNINGS REPORT
For the full year, revenues are projected in the range of $298-304 million, up 17-20% year-over-year.
During the previous earnings conference call, the management had laid out its plans for the company’s growth. The management plans to invest in efforts that drive enterprise sales, fuel growth in its core self-serve channel, and expand its international business.
SurveyMonkey expects to generate significant cash flow over the course of the year while aiming to position the company for an even stronger 2020.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
